Suppr超能文献

肿瘤微环境对前列腺癌进展的调控

Regulation of prostate cancer progression by the tumor microenvironment.

作者信息

Shiao Stephen L, Chu Gina Chia-Yi, Chung Leland W K

机构信息

Departments of Radiation Oncology and Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

出版信息

Cancer Lett. 2016 Sep 28;380(1):340-8. doi: 10.1016/j.canlet.2015.12.022. Epub 2016 Jan 28.

Abstract

Prostate cancer remains the most frequently diagnosed cancer in men in North America, and despite recent advances in treatment patients with metastatic disease continue to have poor five-year survival rates. Recent studies in prostate cancer have revealed the critical role of the tumor microenvironment in the initiation and progression to advanced disease. Experimental data have uncovered a reciprocal relationship between the cells in the microenvironment and malignant tumor cells in which early changes in normal tissue microenvironment can promote tumorigenesis and in turn tumor cells can promote further pro-tumor changes in the microenvironment. In the tumor microenvironment, the presence of persistent immune infiltrates contributes to the recruitment and reprogramming of other non-immune stromal cells including cancer-associated fibroblasts and a unique recently identified population of metastasis-initiating cells (MICs). These MICs, which can also be found as part of the circulating tumor cell (CTC) population in PC patients, promote cancer cell transformation, enhance metastatic potential and confer therapeutic resistance. MICs act can on other cells within the tumor microenvironment in part by secreting exosomes that reprogram adjacent stromal cells to create a more favorable tumor microenvironment to support continued cancer growth and progression. We review here the current data on the intricate relationship between inflammation, reactive stroma, tumor cells and disease progression in prostate cancer.

摘要

前列腺癌仍然是北美男性中最常被诊断出的癌症,尽管最近治疗方面取得了进展,但转移性疾病患者的五年生存率仍然很低。最近对前列腺癌的研究揭示了肿瘤微环境在疾病起始和进展为晚期过程中的关键作用。实验数据揭示了微环境中的细胞与恶性肿瘤细胞之间的相互关系,其中正常组织微环境的早期变化可促进肿瘤发生,反过来肿瘤细胞又可促进微环境中进一步的促肿瘤变化。在肿瘤微环境中,持续存在的免疫浸润有助于招募和重编程其他非免疫基质细胞,包括癌症相关成纤维细胞和最近新发现的独特的转移起始细胞(MIC)群体。这些MIC在前列腺癌患者中也可作为循环肿瘤细胞(CTC)群体的一部分被发现,它们促进癌细胞转化,增强转移潜能并赋予治疗抗性。MIC的作用部分是通过分泌外泌体来实现的,这些外泌体重编程相邻的基质细胞以创造更有利于肿瘤生长和进展的肿瘤微环境。我们在此回顾目前关于前列腺癌中炎症、反应性基质、肿瘤细胞和疾病进展之间复杂关系的数据。

相似文献

1
Regulation of prostate cancer progression by the tumor microenvironment.
Cancer Lett. 2016 Sep 28;380(1):340-8. doi: 10.1016/j.canlet.2015.12.022. Epub 2016 Jan 28.
3
Elevation of Stromal-Derived Mediators of Inflammation Promote Prostate Cancer Progression in African-American Men.
Cancer Res. 2018 Nov 1;78(21):6134-6145. doi: 10.1158/0008-5472.CAN-17-3810. Epub 2018 Sep 4.
4
Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
J Urol. 2005 Jan;173(1):10-20. doi: 10.1097/01.ju.0000141582.15218.10.
6
Metabolic reprogramming of stromal fibroblasts through p62-mTORC1 signaling promotes inflammation and tumorigenesis.
Cancer Cell. 2014 Jul 14;26(1):121-135. doi: 10.1016/j.ccr.2014.05.004. Epub 2014 Jul 4.
8
The reactive stroma microenvironment and prostate cancer progression.
Endocr Relat Cancer. 2012 Oct 30;19(6):R187-204. doi: 10.1530/ERC-12-0085. Print 2012 Dec.
9
MYC Mediates Large Oncosome-Induced Fibroblast Reprogramming in Prostate Cancer.
Cancer Res. 2017 May 1;77(9):2306-2317. doi: 10.1158/0008-5472.CAN-16-2942. Epub 2017 Feb 15.
10
Advanced prostate cancer: reinforcing the strings between inflammation and the metastatic behavior.
Prostate Cancer Prostatic Dis. 2012 Sep;15(3):213-21. doi: 10.1038/pcan.2011.64. Epub 2011 Dec 20.

引用本文的文献

3
The differential role of IL-33 and IL-38 in prostate cancer, contradictory roles.
Front Immunol. 2025 Jun 18;16:1623038. doi: 10.3389/fimmu.2025.1623038. eCollection 2025.
4
Prostate cancer immunotherapy-based strategies: an updated review emphasizing immune checkpoint inhibitors.
Front Immunol. 2025 Jun 18;16:1583363. doi: 10.3389/fimmu.2025.1583363. eCollection 2025.
5
BioBERT-powered synergy: advanced bibliometric and molecular insights into prostate cancer bone metastasis.
Front Immunol. 2025 Jun 18;16:1562559. doi: 10.3389/fimmu.2025.1562559. eCollection 2025.
9
Molecular Mechanisms of Castration-Resistant Prostate Cancer Progression.
Cureus. 2025 May 9;17(5):e83813. doi: 10.7759/cureus.83813. eCollection 2025 May.

本文引用的文献

2
Immune Infiltration and Prostate Cancer.
Front Oncol. 2015 Jul 8;5:128. doi: 10.3389/fonc.2015.00128. eCollection 2015.
3
The DNA damage response and immune signaling alliance: Is it good or bad? Nature decides when and where.
Pharmacol Ther. 2015 Oct;154:36-56. doi: 10.1016/j.pharmthera.2015.06.011. Epub 2015 Jul 3.
4
Inflammation and cancer: advances and new agents.
Nat Rev Clin Oncol. 2015 Oct;12(10):584-96. doi: 10.1038/nrclinonc.2015.105. Epub 2015 Jun 30.
5
The biology of circulating tumor cells.
Oncogene. 2016 Mar 10;35(10):1216-24. doi: 10.1038/onc.2015.192. Epub 2015 Jun 8.
6
Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab.
Cancer Immunol Res. 2015 Sep;3(9):1008-16. doi: 10.1158/2326-6066.CIR-14-0227. Epub 2015 May 12.
7
Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer.
Oncotarget. 2015 Jun 10;6(16):14360-73. doi: 10.18632/oncotarget.3965.
8
Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy.
Nature. 2015 May 7;521(7550):94-8. doi: 10.1038/nature14395. Epub 2015 Apr 29.
9
Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer.
Br J Cancer. 2015 Apr 14;112(8):1340-8. doi: 10.1038/bjc.2015.74. Epub 2015 Mar 31.
10
Macrophages and therapeutic resistance in cancer.
Cancer Cell. 2015 Apr 13;27(4):462-72. doi: 10.1016/j.ccell.2015.02.015. Epub 2015 Apr 6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验